We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+8.92%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$4.08B
AUM Growth
+$157M
Cap. Flow
-$183M
Cap. Flow %
-4.49%
Top 10 Hldgs %
70.38%
Holding
43
New
5
Increased
7
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$93.7M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$58.2M
3
DNLI icon
Denali Therapeutics
DNLI
+$28.2M
4
QGEN icon
Qiagen
QGEN
+$27.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.4M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$166M
2
UHS icon
Universal Health Services
UHS
+$102M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$43.8M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$43M
5
QDEL icon
QuidelOrtho
QDEL
+$29.5M

Sector Composition

Rank Sector Weight
1 Healthcare 67.95%
2 Consumer Staples 1.12%
3 Consumer Discretionary 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$1.15B 28.2%
2,200,000
+200,000
+10% +$99.6M
ZBH icon
2
Zimmer Biomet
ZBH
$18.8B
$254M 6.23%
1,925,000
– –
UHS icon
3
Universal Health Services
UHS
$10.2B
$228M 5.59%
1,250,000
-620,000
-33% -$102M
BAX icon
4
Baxter International
BAX
$12.8B
$214M 5.24%
5,000,000
– –
THC icon
5
Tenet Healthcare
THC
$22.2B
$200M 4.89%
1,900,000
-1,845,000
-49% -$166M
VTRS icon
6
Viatris
VTRS
$20.8B
$194M 4.76%
16,250,000
-2,250,000
-12% -$27.1M
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
$169M 4.15%
7,800,000
+800,000
+11% +$17.8M
MYGN icon
8
Myriad Genetics
MYGN
$476M
$163M 3.99%
7,635,000
– –
MDT icon
9
Medtronic
MDT
$112B
$161M 3.95%
1,850,000
– –
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$16.1B
$138M 3.39%
1,150,000
+475,000
+70% +$58.2M
GMED icon
11
Globus Medical
GMED
$11.1B
$134M 3.29%
2,500,000
+250,000
+11% +$13.4M
PTCT icon
12
PTC Therapeutics
PTCT
$6.18B
$116M 2.85%
4,000,000
– –
SEM
13
DELISTED
Select Medical
SEM
$103M 2.51%
6,310,400
– –
BKD icon
14
Brookdale Senior Living
BKD
$3.55B
$102M 2.51%
15,500,000
– –
GSK icon
15
GSK
GSK
$107B
$93.2M 2.29%
2,175,000
– –
BIIB icon
16
Biogen
BIIB
$30.9B
$86.3M 2.11%
+400,000
New +$93.7M
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.64B
$75.7M 1.86%
585,000
-215,000
-27% -$26.3M
PFE icon
18
CALL
Pfizer
PFE
$143B
$69.4M 1.7%
2,500,000
-1,420,000
-36% -$39.4M
ZIMV
19
DELISTED
ZimVie
ZIMV
$53.6M 1.31%
3,250,000
– –
QGEN icon
20
Qiagen
QGEN
$8.62B
$52M 1.27%
1,176,389
+596,410
+103% +$27.2M
PRGO icon
21
Perrigo
PRGO
$1.44B
$48.9M 1.2%
1,520,000
-330,000
-18% -$10.4M
COLL icon
22
Collegium Pharmaceutical
COLL
$1.18B
$33.1M 0.81%
852,900
-197,100
-19% -$6.9M
DNLI icon
23
Denali Therapeutics
DNLI
$3.79B
$30.8M 0.75%
+1,500,000
New +$28.2M
HLF icon
24
Herbalife
HLF
$1.3B
$30.1M 0.74%
3,000,000
+1,000,000
+50% +$10.8M
OSUR icon
25
OraSure Technologies
OSUR
$273M
$26.1M 0.64%
4,250,000
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Camber Capital Management held 43 positions worth $4.08B, up 4% from $3.92B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Camber Capital Management withdrew a net $183M in Q1 2024, closing 7 positions and reducing 8 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $43.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in Biogen worth $86.3M.

  • Camber Capital Management's largest Q1 2024 buy was Biogen: 400,000 shares worth $86.3M.
  • Camber Capital Management added most to Jazz Pharmaceuticals in Q1 2024, an estimated $58.2M increase.
  • Camber Capital Management's biggest Q1 2024 reduction was Tenet Healthcare, cutting an estimated $166M.
  • Camber Capital Management fully exited Ionis Pharmaceuticals in Q1 2024, selling an estimated $43.8M.
  • Camber Capital Management's ten largest holdings make up 70% of its $4.08B portfolio in Q1 2024.
  • Camber Capital Management opened 5 new positions and closed 7 in Q1 2024.
  • Camber Capital Management's portfolio value rose 4% quarter-over-quarter to $4.08B.

Based on Camber Capital Management's 13F filing for Q1 2024, filed 15 May 2024.